Mason Carrico
Stock Analyst at Stephens & Co.
(2.17)
# 2,902
Out of 5,015 analysts
74
Total ratings
40.91%
Success rate
-1.67%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HOLX Hologic | Reiterates: Overweight | $78 | $67.76 | +15.11% | 5 | Sep 18, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $9.10 | +20.88% | 2 | Sep 2, 2025 | |
| NTRA Natera | Reiterates: Overweight | $183 | $169.27 | +8.11% | 5 | Aug 15, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $31.85 | +110.36% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $93.86 | +11.87% | 8 | May 20, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $1.8 | $1.42 | +26.76% | 5 | May 15, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $11.47 | +22.06% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $14.38 | +178.16% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $82.56 | +39.29% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $34.80 | +29.31% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $64.22 | -14.36% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $3.85 | +55.84% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $26.68 | -36.28% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $38.94 | +33.54% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $7.50 | +166.67% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $23.08 | +77.64% | 7 | Jan 2, 2025 |
Hologic
Sep 18, 2025
Reiterates: Overweight
Price Target: $78
Current: $67.76
Upside: +15.11%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $9.10
Upside: +20.88%
Natera
Aug 15, 2025
Reiterates: Overweight
Price Target: $183
Current: $169.27
Upside: +8.11%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $31.85
Upside: +110.36%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $93.86
Upside: +11.87%
Pacific Biosciences of California
May 15, 2025
Reiterates: Overweight
Price Target: $1.8
Current: $1.42
Upside: +26.76%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $11.47
Upside: +22.06%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $14.38
Upside: +178.16%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $82.56
Upside: +39.29%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $34.80
Upside: +29.31%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $64.22
Upside: -14.36%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $3.85
Upside: +55.84%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $26.68
Upside: -36.28%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $38.94
Upside: +33.54%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $7.50
Upside: +166.67%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $23.08
Upside: +77.64%